Recent data suggest that plasma proteins originating from the adipose tissue, such as endocannabinoids, leptin, and adiponectin, play a central role in the regulation and control of coronary circulatory function in obesity (4) . A clinical study investigating the relationship between body weight and coronary circulation in subjects without traditional coronary risk factors showed the progression of endothelium-dependent coronary vasomotion impairment in overweight subjects to total vasodilatory capacity dysfunction in obese individuals (3) . These findings imply that obesity is an independent mediator of coronary artery disease rather than an epiphenomenon to other traditional risk factors commonly associated with obesity, such as diabetes mellitus, hypertension, dyslipidemia, and insulin resistance (5) . Noninvasive diagnostic imaging studies that can identify coronary circulatory and metabolic abnormalities early in the progression of cardiovascular disease may help improve patient outcome in such patients.
Myocardial blood flow assessed at rest and during stress with positron emission tomographic (PET) imaging provides a noninvasive surrogate of coronary circulatory function (6) . PET myocardial perfusion imaging uses radionuclides with half-lives that are considerably shorter than those used in single-photon emission computed tomography (SPECT), such as rubidium-82, with a 75-s halflife, resulting in lower radiation exposure than with SPECT (7). Moreover, PET images have better spatial and temporal resolution compared with SPECT and allow reliable and accurate soft tissue attenuation correction (8) . The latter is particularly relevant for patients who are obese or have large body habitus. When combined with tracer kinetic modeling, PET imaging permits the noninvasive assessment of the coronary circulatory function in absolute (ml/min/g) terms (9, 10) .
In a recent multicenter observational registry, consisting of more than 7,000 patients with known or suspected coronary artery disease, the extent and severity of ischemia and scar as assessed by rubidium-82 vasodilator PET myocardial perfusion imaging provided significant incremental risk estimates of cardiac death and all-cause mortality compared with traditional coronary risk factors (11) . The risk-adjusted hazard ratio of cardiac death increased with each 10% increment in stress myocardial perfusion defect from mild to moderate to severe, resulting in a nearly 5-fold higher hazard of cardiac death among patients with severe PET perfusion defects compared with those with normal PET results (11) . Certainly, there are inherent limitations in such nonrandomized, observational multicenter registry studies that use site-specific protocols on a variety of PET cameras from different manufacturers, applying different attenuation correction methods and interpretation algorithms. Demographic information on patients was somewhat limited, because fundamental information such as symptom status, left ventricular ejection fraction, and laboratory values, such as serum glucose, lipid profile, and renal function, were missing; hence, classic risk scores such as the Framingham score or the coronary risk score of the European Society of Cardiology could not be calculated. However, the geographic diversity of the patients, protocols, and cameras may also be seen as a strength. Such registry data may more closely reflect real-world experience than a tightly monitored randomized study.
In this issue of iJACC, Chow et al. (12) further extend the prognostic role of rubidium-82 vasodilator PET myocardial perfusion imaging by stratifying the aforementioned patient population by body mass index (BMI) and thus providing a look at the performance of PET imaging in a population known to be difficult to assess by conventional imaging studies. The detrimental effects of soft tissue attenuation, which tends to degrade image quality and increase interpretive errors, have long been recognized with SPECT (13) . Although more recent SPECT cameras include hardware and software solutions for attenuation correction, they remain nonideal and less robust than attenuation correction algorithms applied with PET imaging. Beyond differences in soft tissue attenuation correction, PET imaging provides higher myocardial count density at a shorter image acquisition time than SPECT and less scatter of activity from adjacent subdiaphragmatic visceral structures into the myocardial region, allowing a finer reslicing of the left ventricular myocardium.
As for echocardiography, despite steady improvements in transducer technology and increasing use of left heart contrast, obese patients remain a challenge for (stress) echocardiographers: "Image quality is subject to the body habitus of patients, and ultrasound imaging in general may yet become a casualty of the obesity epidemic" (14) . Obesity also reduces image quality and/or necessitates higher radiation doses when applying cardiac computed tomography (15, 16) . Cardiac magnetic resonance is the only imaging technique largely immune to image deterioration due to obesity.
Remarkably, in the study by Chow et al. (12) , only 22% of patients had normal BMIs (<25 kg/m 2 ), underlining the fact that obesity really is the "new normal." Another full 22% qualified as severely obese (BMI $35 kg/m 2 ). The important findings of the study are as follows: patients a more precise risk for future death, measured by the "net reclassification improvement" (NRI), and did so equally well in all BMI categories.
Reclassification of risk is a relatively novel concept, which determines how many patients are shifted to more appropriate risk categories after the evaluation of new disease markers (17, 18) . In the present study, reclassification was quantified as "category-free NRI" (19, 20) . The category-free NRI, different from the conventional "categorical" NRI, does not depend on the number and distribution of levels of cardiovascular risk into which patients are categorized. Note, however, that the category-free NRI may be several-fold higher in absolute value than the conventional "categorical" NRI (21) and, therefore, cannot be directly compared with categorical NRIs for diagnostic markers or procedures reported in the published research. For example, in the first report from the PET registry (11), PET imaging had a categorical NRI of 11.6% but a category-free NRI of 54% for the prediction of cardiac death. In the present study (12) , a category-free NRI of 46% (95% confidence interval: 31% to 61%) was calculated for the entire study group for which data on cardiac death were available, and similar NRIs were calculated across the different BMI groups.
An interesting aspect of this study is the reappearance of the debated "obesity paradox" (22, 23) . In the cohort of subjects studied, overall and cardiac mortality were lower in patients with higher BMIs. This of course does not prove that obesity protects against death. As the investigators point out, interaction with age (inversely associated with BMI) as well as with dyspnea symptoms and referral likelihood (both positively associated with BMI) may be the reason for this finding, similar to the better known "smokers' paradox."
The investigators conclude that myocardial perfusion PET imaging is an attractive option for risk stratification in all patients with suspected or known coronary artery disease, including those with increased BMIs. Is PET imaging therefore the next wave of prognostic testing in the growing population of obese patients? Although there is little doubt that myocardial perfusion PET imaging adds prognostic power to classic risk factors, there are no large head-to-head comparisons of the prognostic power of PET imaging with other tests. In particular, prognostic comparisons with current stress echocardiography or cardiac magnetic resonance imaging are lacking. Furthermore, statistical measures of predictive power, such as the ones used in this study (Harrell's c or the category-free NRI) are not easy to translate into clinically meaningful information or to compare between studies. Finally, as we have learned from new risk markers for coronary artery disease, heart failure, and other conditions, adding prognostic power is not enough for a test to be clinically meaningful (24) . Rather, information garnered from a diagnostic test needs to guide patient management decisions. Ultimately, such marker-based patient management decisions should improve patient outcome. This is a formidable threshold to widespread introduction of new diagnostic techniques, which is similarly faced by other candidate tests, such as ultrasound measurement of intima-media thickness of the carotid artery or coronary calcium scoring by computed tomography. For PET imaging in particular, availability and cost further limit its large-scale adoption at this point. Nonetheless, the study of Chow et al. (12) shows convincingly that PET imaging is a valid prognostic instrument to consider for risk assessment of the large and growing group of patients with obesity.
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